# An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

> **NCT04453085** · PHASE1,PHASE2 · COMPLETED · sponsor: **JCR Pharmaceuticals Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Mucopolysaccharidosis I

## Interventions

- **DRUG:** JR-171

## Key facts

- **NCT ID:** NCT04453085
- **Lead sponsor:** JCR Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2025-05-02
- **Final completion:** 2025-05-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453085, "An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04453085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*